REZOLUTE RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR ERSODETUG IN THE TREATMENT OF HYPOGLYCEMIA DUE TO CONGENITAL HYPERINSULINISM

Reuters · 01/07 13:00

Please log in to view news